From: A new promising way of maintenance therapy in advanced ovarian cancer: a comparative clinical study
Characteristic | Arm 1 (n = 46) | Arm 2 (n = 76) | Arm 3 (n = 42) | Arms 2 + 3 (n = 118) | Arm 5 (n = 80) |
---|---|---|---|---|---|
At screening | |||||
 MS ± SD | 19.68 ± 8.52 | 19.19 ± 8.90 | 18.19 ± 7.74 | 18.84 ± 8.49 | 19.71 ± 8.94 |
 p* | 0.9868 | 0.7207 | 0.3619 | 0.4953 |  |
After combined treatment | |||||
 MS ± SD | 31.39 ± 8.20 | 31.25 ± 7.77 | 31.66 ± 5.57 | 31.39 ± 7.05 | 31.25 ± 6.58 |
 p* | 0.9135 | 0.9999 | 0.7376 | 0.8870 |  |
At the end of the study | |||||
 MS ± SD | 34.59 ± 21.53 | 29.28 ± 20.33 | 30.01 ± 23.19 | 29.57 ± 21.34 | 34.83 ± 19.21 |
 p* | 0.9644 | 0.2494 | 0.3970 | 0.2588 |  |